Xanthic Biopharma Inc. Announces Official Filing of Patents to Protect Company's Proprietary Manufacturing Process and Products

TORONTO, March 7, 2018 /CNW/ - Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) ("Xanthic") is pleased to announce the recent filing of a patent application. The application claims patent protection for the Company's proprietary processes to powderize active ingredients in cannabis, including both THC and CBD, in order to make them water soluble and significantly increase the bioavailability of the active ingredients.  The patent application also claims protection for powdered cannabis products made according to the Company's proprietary processes. The cannabis industry faces an ongoing challenge in this area as THC and CBD are typically only oil-soluble making the creation of infused products challenging. The Company's patent-pending processes and products address this challenge.  The Company's patent application is pending and has yet to undergo examination at the Patent Office. However, the patent application provides the Company with a priority filing date ahead of any subsequently filed potentially comparable patent applications.

Tim Moore, the CEO of Xanthic, commented, "Xanthic is extremely excited to have developed this industry-leading technology. The Company's technology provides a competitive advantage in the marketplace and we have taken the logical step of seeking  patent protection for the Company's proprietary processes and products. Our break through process allows for full spectrum cannabinoid water solubility with maximum bioavailability. This is an industry first and will add a great deal of value for our strategic partners."

About Xanthic

Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis, and cannabis-infused products which deliver consistent THC and/or CBD levels. Using proprietary processes, Xanthic allows its strategic partners to deliver superior cannabinoid solubility and consistency versus competitive infused products.

Disclaimer:

Xanthic's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulation S under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.

SOURCE Xanthic BioPharma

Tim Moore, CEO, Xanthic Biopharma Inc., [email protected], Phone: [phone], [email protected]